Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
October 2011, Vol 2, No 6
October 2011, Vol 2, No 6
Diagnosing Melanoma Early May Soon Be Easier: MelaFind Gets Approvable Letter
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
On September 26, 2011, the FDA issued an approvable letter to Mela Sciences, the manufacturer of MelaFind, an investigational diagnostic device for early melanoma.
Read Article
Ginger Root Cost-Effective for Preventing Colon Cancer
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
In a new study funded by the National Cancer Institute and the University of Michigan Clinical Research Center, inexpensive ginger supplements reduced markers of colon inflammation, indicating that ginger root may be beneficial in preventing colon cancer (Zick SM, et al. Cancer Prev Res [Phila]. 2011 Oct 11. Epub ahead of print).
Read Article
US Patients Get New Cancer Drugs Faster than in Europe
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
Read Article
PET Imaging an Effective Tool for Tailoring Therapy in Advanced Lung Cancer
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
Positron emission tomography (PET) is a promising approach for differentiating which patients with inoperable lung cancer will and will not benefit from additional treatment after standard chemotherapy/radiation therapy.
Read Article
How to Assess the Value of Clinical Interventions
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
Another report in the same issue of the Annals of Internal Medicine focuses on the relevance of 3 concepts that can help in understanding the value of clinical interventions for those involved in clinical decisions (Owens DK, et al. Ann Intern Med. 2011;154:174-180).
Read Article
Value of Cost-Effectiveness Analyses for Clinical Practice Outlined by NICE
Value Propositions
,
Value Peer-spectives
October 2011, Vol 2, No 6
The National Institute for Health and Clinical Excellence (NICE) has issued a report (Wonderling D, et al. Ann Intern Med. 2011;154:758-765) explaining the process and value of cost-effectiveness assessments and how these inform recommendations and decisions regarding clinical questions made by the UK National Clinical Guidelines Centre.
Read Article
Novel Agents Improve Outcomes as Maintenance Therapy for Multiple Myeloma
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
Thalidomide (Thalomid), lenalidomide (Revlimid), and bortezomib (Velcade) have all shown benefit in the maintenance setting, said Steven Devine, MD, Professor of Medicine and Director of the Blood and Marrow Transplant Program, Ohio State University Comprehensive Cancer Center, Columbus, during the recent National Comprehensive Cancer Network (NCCN) 6th Congress on Hematologic Malignancies.
Read Article
Therapy-Associated Complications Significantly Increase Cost of Cancer Care
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—The cost of cancer therapies is a growing concern not only for patients but also for providers and payers. Addressing the cost burden for those involved in cancer care is becoming a priority that cannot be avoided with the growing role of targeted therapies in oncology.
Read Article
The Road to Personalized Medicine Is Strewn with Obstacles
By
Audrey Andrews
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—With recognition of common tumor mutations and a pipeline full of biologic agents that target them, personalized medicine should be all but a fait accompli. But one expert told attendees at the European Society for Medical Oncology’s 2011 European Multidisciplinary Cancer Congress, “We may be overpromising our patients.”
Read Article
The First NCQA-Recognized Medical Home in Oncology
By
John D. Sprandio, MD, FACP
Oncology
October 2011, Vol 2, No 6
The patient-centered medical home (PCMH) model of care has proved successful in overcoming some of the fragmentation of primary care. Dr Sprandio and his colleagues have now demonstrated the value of applying the principles of the medical home to cancer care, with particular implications for oncologists and for payers and unique reimbursement dilemmas.
Read Article
Page 4 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma